nach oben

Current Emergency and Hospital Medicine Reports

Erschienen in:

01.06.2019 | Cardiovascular Care (L Roever, Section Editor)

Complications After Heart Transplantation in Adults: an Update

verfasst von: Kevin S. Shah, Jon A. Kobashigawa

Erschienen in: Current Emergency and Hospital Medicine Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The goal of this review article is to highlight our understanding of potential complications after heart transplantation. We aim to discuss recent advances within the field that directly impact the management of heart transplant recipients. Our target audiences include cardiologists, emergency medicine, and internal medicine providers.

Recent Findings

Heart transplantation remains definitive therapy for end-stage heart failure. Complications after transplant can be divided in to post-operative, early, and late. Complications are related to the differing physiology of the denervated transplant heart as well as the immunosuppressive medications necessitated to maintain graft function. These include primary graft dysfunction, allograft rejection, chronic renal insufficiency, cardiac allograft vasculopathy, and malignancy.

Summary

The anticipation and management of complications in patients after receiving a heart transplant involve a comprehensive understanding of the differences in the transplanted heart and effects of immunosuppressive therapies.

Colvin M, Smith JM, Hadley N, et al. OPTN/SRTR 2016 Annual data report. Heart Am J Transplant. 2018. https://doi.org/10.1111/ajt.14561.

Kidambi S, Mohamedali B, Bhat G. Clinical outcomes in sensitized heart transplant patients bridged with ventricular assist devices. Clin Transpl. 2015;29:499–505. https://doi.org/10.1111/ctr.12540.CrossRef

Kilic A, Weiss ES, Yuh DD, Shah AS, Conte JV. Factors associated with 5-year survival in older heart transplant recipients. J Thorac Cardiovasc Surg. 2012;143:468–74.CrossRefPubMed

• Kobashigawa J, Colvin M, Potena L, et al. The management of antibodies in heart transplantation: an ISHLT consensus document. J Hear Lung Transplant. 2018. https://doi.org/10.1016/j.healun.2018.01.1291 This consensus document reviews the detection, interpretation, and management of antibodies in patients awaiting heart transplant.

Lund LH, Khush KK, Cherikh WS, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report—2017; focus theme: allograft ischemic time. J Hear Lung Transplant. 2017;36:1037–46.CrossRef

Mohanty PK, Thames MD, Arrowood JA, Sowers JR, McNamara C, Szentpetery S. Impairment of cardiopulmonary baroreflex after cardiac transplantation in humans. Circulation. 1987;75:914–21. https://doi.org/10.1161/01.CIR.75.5.914.CrossRefPubMed

Schwaiblmair M, Von Scheidt W, Überfuhr P, Ziegler S, Schwaiger M, Reichart B, et al. Functional significance of cardiac reinnervation in heart transplant recipients. J Hear Lung Transplant. 1999;18:838–45. https://doi.org/10.1016/S1053-2498(99)00048-0.CrossRef

Bexton RS, Milne JR, Cory-Pearce R, English TAH, John Camm A. Effect of beta blockade on exercise response after cardiac transplantation. Heart. 1983;49:584–8. https://doi.org/10.1136/hrt.49.6.584.CrossRef

Scott AL. Atropine. Encycl Toxicol Third Ed. 2014. https://doi.org/10.1016/B978-0-12-386454-3.00695-3.

10.

•• Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010. https://doi.org/10.1016/j.healun.2010.05.034 These guidelines summarize the current recommendations regarding management of patients after heart transplantations and quantifies the strength of evidence behind current recommendations.

11.

Williams M. Adenosine. xPharm Compr Pharmacol Ref. 2011. https://doi.org/10.1016/B978-008055232-3.61169-9.

12.

Kittleson MM, Kobashigawa JA. Long-term care of the heart transplant recipient. Curr Opin Organ Transplant. 2014;19:515–24. https://doi.org/10.1097/MOT.0000000000000117.CrossRefPubMed

13.

Rose AG. Understanding the pathogenesis and the pathology of hyperacute cardiac rejection. Cardiovasc Pathol. 2002;11:171–6. https://doi.org/10.1016/S1054-8807(01)00097-7.CrossRefPubMed

14.

Vega E, Schroder J, Nicoara A. Postoperative management of heart transplantation patients. Best Pract Res Clin Anaesthesiol. 2017;31:201–13. https://doi.org/10.1016/j.bpa.2017.06.002.CrossRefPubMed

15.

Quin JA, Tauriainen MP, Huber LM, McIntire DD, Kaiser PA, Ring WS, et al. Predictors of pericardial effusion after orthotopic heart transplantation. J Thorac Cardiovasc Surg. 2002;124:979–83. https://doi.org/10.1067/mtc.2002.124387.CrossRefPubMed

16.

Hauptman PJ, Couper GS, Aranki SF, Kartashov A, Mudge GH, Loh E. Pericardial effusions after cardiac transplantation. J Am Coll Cardiol. 1994;23:1625–9. https://doi.org/10.1016/0735-1097(94)90666-1.CrossRefPubMed

17.

Roy CL, Minor MA, Brookhart MA, Choudhry NK. Does this patient with a pericardial effusion have cardiac tamponade? J Am Med Assoc. 2007;297:1810–8. https://doi.org/10.1001/jama.297.16.1810.CrossRef

18.

Nicoara A, Ruffin D, Cooter M, et al. Primary graft dysfunction after heart transplantation: incidence, trends, and associated risk factors. Am J Transplant. 2017. https://doi.org/10.1111/ajt.14588.

19.

•• Kobashigawa J, Zuckermann A, Macdonald P, et al. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Hear Lung Transplant. 2014. https://doi.org/10.1016/j.healun.2014.02.027 This statement summarizes the discussion from a consensus conference on the definition and management strategies for primary graft dysfunction.

20.

Stobierska-Dzierzek B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol. 2001;38:923–31. https://doi.org/10.1016/S0735-1097(01)01486-3.CrossRefPubMed

21.

Konstam MA, Kiernan MS, Bernstein D, et al. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. Circulation. 2018. https://doi.org/10.1161/CIR.0000000000000560.

22.

McGiffin DC, Kirklin JK, Naftel DC, Bourge RC (1997) Competing outcomes after heart transplantation: a comparison of eras and outcomes. J Hear Lung Transplant

23.

Cantillon DJ, Tarakji KG, Hu T, Hsu A, Smedira NG, Starling RC, et al. Long-term outcomes and clinical predictors for pacemaker-requiring bradyarrhythmias after cardiac transplantation: analysis of the UNOS/OPTN cardiac transplant database. Hear Rhythm. 2010;7:1567–71. https://doi.org/10.1016/j.hrthm.2010.06.026.CrossRef

24.

Vaseghi M, Boyle NG, Kedia R, Patel JK, Cesario DA, Wiener I, et al. Supraventricular tachycardia after orthotopic cardiac transplantation. J Am Coll Cardiol. 2008;51:2241–9. https://doi.org/10.1016/j.jacc.2008.02.065.CrossRefPubMed

25.

Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report—2012. J Hear Lung Transplant. 2012;31:1052–64. https://doi.org/10.1016/j.healun.2012.08.002.CrossRef

26.

Kobashigawa JA, Kirklin JK, Naftel DC, Bourge RC, Ventura HO, Mohanty PK, Cintron GB, Bhat G (1993) Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. J Hear Lung Transplant Off Publ Int Soc Hear Transplant

27.

Long B, Koyfman A. The emergency medicine approach to transplant complications. Am J Emerg Med. 2016;34:2200–8. https://doi.org/10.1016/j.ajem.2016.08.049.CrossRefPubMed

28.

Vermes E, Pantaléon C, Auvet A, Cazeneuve N, Machet MC, Delhommais A, et al. Cardiovascular magnetic resonance in heart transplant patients: diagnostic value of quantitative tissue markers: T2 mapping and extracellular volume fraction, for acute rejection diagnosis. J Cardiovasc Magn Reson. 2018;20:1–11.CrossRef

29.

Usman AA, Taimen K, Wasielewski M, et al. Cardiac magnetic resonance T2 mapping in the monitoring and follow-up of acute cardiac transplant rejection: a pilot study. Circ Cardiovasc Imaging. 2012;5:782–90. https://doi.org/10.1161/CIRCIMAGING.111.971101.CrossRefPubMed

30.

Labarrere CA, Jaeger BR. Biomarkers of heart transplant rejection: the good, the bad, and the ugly! Transl Res. 2012;159:238–51. https://doi.org/10.1016/j.trsl.2012.01.018.CrossRefPubMed

31.

Butler CR, Thompson R, Haykowsky M, Toma M, Paterson I. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review. J Cardiovasc Magn Reson. 2009. https://doi.org/10.1186/1532-429X-11-7.

32.

Deckers JW, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J Am Coll Cardiol. 1992;19:43–7. https://doi.org/10.1016/0735-1097(92)90049-S.CrossRefPubMed

33.

Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Hear Lung Transplant. 2007. https://doi.org/10.1016/j.healun.2007.10.017.

34.

Berry GJ, Burke MM, Andersen C, et al. The 2013 international society for heart and lung transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Hear Lung Transplant. 2013. https://doi.org/10.1016/j.healun.2013.08.011.

35.

Deng MC. The AlloMap™ genomic biomarker story: 10 years after. Clin Transpl. 2017. https://doi.org/10.1111/ctr.12900.

36.

De Vlaminck I, Valantine HA, Snyder TM, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014;6:241ra77. https://doi.org/10.1126/scitranslmed.3007803.CrossRefPubMedPubMedCentral

37.

Loupy A, van Huyen JPD, Hidalgo L, et al. Gene expression profiling for the identification and classification of antibody-mediated heart rejection. Circulation. 2017. https://doi.org/10.1161/CIRCULATIONAHA.116.022907.

38.

Davis MK, Hunt SA. State of the art: cardiac transplantation. Trends Cardiovasc Med. 2014;24:341–9. https://doi.org/10.1016/j.tcm.2014.08.004.CrossRefPubMed

39.

Fishman JA. Infections in solid-organ transplant recipients. N Engl J Med. 2007;357:2601–14.CrossRefPubMed

40.

Varr BC, Restaino SW, Farr M, Scully B, Colombo PC, Naka Y, et al. Infectious complications after cardiac transplantation in patients bridged with mechanical circulatory support devices versus medical therapy. J Hear Lung Transplant. 2016;35:1116–23. https://doi.org/10.1016/j.healun.2016.04.016.CrossRef

41.

Brooks RG, Hofflin JM, Jamieson SW, Stinson EB, Remington JS. Infectious complications in heart-lung transplant recipients. Am J Med. 1985;79:412–22. https://doi.org/10.1016/0002-9343(85)90027-0.CrossRefPubMed

42.

Montoya JG, Giraldo LF, Efron B, Stinson EB, Gamberg P, Hunt S, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis. 2001;33:629–40. https://doi.org/10.1086/322733.CrossRefPubMed

43.

Rubin RH, Kemmerly SA, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis. 2000. https://doi.org/10.1034/j.1399-3062.2000.020303.x.

44.

Delgado JF, Reyne AG, De Dios S, et al. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Hear Lung Transplant. 2015. https://doi.org/10.1016/j.healun.2015.03.015.

45.

Andrikopoulou E, Mather PJ. Current insights: use of Immuknow in heart transplant recipients. Prog Transplant. 2014;24:44–50. https://doi.org/10.7182/pit2014664.CrossRefPubMed

46.

Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006. https://doi.org/10.1097/01.tp.0000234837.02126.70.

47.

Ramzy D, Rao V, Brahm J, Miriuka S, Delgado D, Ross HJ (2005) Cardiac allograft vasculopathy: a review. Can J Surg

48.

Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45:1532–7.CrossRefPubMed

49.

Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Hear Lung Transpl. 2004;23:S187–93.CrossRef

50.

Wever-Pinzon O, Romero J, Kelesidis I, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials. J Am Coll Cardiol. 2014;63:2005–6.CrossRef

51.

Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003. https://doi.org/10.1056/NEJMoa022171.

52.

Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995. https://doi.org/10.1056/NEJM199509073331003.

53.

Youn JC, Stehlik J, Wilk AR, et al. Temporal trends of de novo malignancy development after heart transplantation. J Am Coll Cardiol. 2018. https://doi.org/10.1016/j.jacc.2017.10.077.

54.

Epailly E, Albanell J, Andreassen A, et al. Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions. Clin Transplant. 2011. https://doi.org/10.1111/j.1399-0012.2011.01476.x.

55.

Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–40. https://doi.org/10.1056/NEJMoa021744.CrossRefPubMed

56.

Kolsrud O, Karason K, Holmberg E, Ricksten SE, Felldin M, Samuelsson O, et al. Renal function and outcome after heart transplantation. J Thorac Cardiovasc Surg. 2018;155:1593–1604.e1.CrossRefPubMed

57.

• Andreassen AK, Andersson B, Gustafsson F, et al. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014;14:1828–38. https://doi.org/10.1111/ajt.12809. This trial demonstrated the efficacy of an immunosuppressive strategy in which calcineurin inhibitors are withdrawn early with early introduction of everolimus to preserve long-term renal function. CrossRefPubMed

58.

Birati EY, Rame JE. Post-heart transplant complications. Crit Care Clin. 2014;30:629–37. https://doi.org/10.1016/j.ccc.2014.03.005.CrossRefPubMed

59.

Pickham D, Hickey K, Doering L, Chen B, Castillo C, Drew BJ. Electrocardiographic abnormalities in the first year after heart transplantation. J Electrocardiol. 2014;47:135–9. https://doi.org/10.1016/j.jelectrocard.2013.09.006.CrossRefPubMed

60.

Battes LC, Caliskan K, Rizopoulos D, Constantinescu AA, Robertus JL, Akkerhuis M, et al. Repeated measurements of NT-pro-B-type natriuretic peptide, troponin T or C-reactive protein do not predict future allograft rejection in heart transplant recipients. Transplantation. 2015;99:580–5. https://doi.org/10.1097/TP.0000000000000378.CrossRefPubMed

61.

Baran DA, Zucker MJ, Arroyo LH, et al. A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ Hear Fail. 2011;4:129–37. https://doi.org/10.1161/CIRCHEARTFAILURE.110.958520.CrossRef

62.

Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118. https://doi.org/10.1016/S0162-3109(00)00188-0.CrossRefPubMed

63.

Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy. 2010;30:1044–56. https://doi.org/10.1592/phco.30.10.1044.CrossRefPubMed

64.

Ruan V, Czer LSC, Awad M, et al. Use of anti-thymocyte globulin for induction therapy in cardiac transplantation: a review. Transplant Proc. 2017. https://doi.org/10.1016/j.transproceed.2016.11.034.

65.

Mondal D. Valganciclovir. xPharm Compr Pharmacol Ref. 2011. https://doi.org/10.1016/B978-008055232-3.62842-9.

66.

Gleckman R, Blagg N, Joubert DW. Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacother J Hum Pharmacol Drug Ther. 1981;1:14–9. https://doi.org/10.1002/j.1875-9114.1981.tb03548.x.CrossRef

67.

Khan M, Kalahasti V, Rajagopal V, et al. Incidence of atrial fibrillation in heart transplant patients: long-term follow-up. J Cardiovasc Electrophysiol. 2006. https://doi.org/10.1111/j.1540-8167.2006.00497.x.

68.

Nof E, Stevenson WG, Epstein LM, Tedrow UB, Koplan BA. Catheter ablation of atrial arrhythmias after cardiac transplantation: findings at EP study utility of 3-D mapping and outcomes. J Cardiovasc Electrophysiol. 2013;24:498–502. https://doi.org/10.1111/jce.12078.CrossRefPubMed

69.

Flyer JN, Zuckerman WA, Richmond ME, Anderson BR, Mendelsberg TG, McAllister JM, et al. Prospective study of adenosine on atrioventricular nodal conduction in pediatric and young adult patients after heart transplantation clinical perspective. Circulation. 2017;135:2485–93. https://doi.org/10.1161/CIRCULATIONAHA.117.028087.CrossRefPubMedPubMedCentral

70.

Chang HY, Lo LW, Feng AN, Chiang MC, Yin WH, Young MS, et al. Long-term follow-up of arrhythmia characteristics and clinical outcomes in heart transplant patients. Transplant Proc. 2013;45:369–75. https://doi.org/10.1016/j.transproceed.2012.09.116.CrossRefPubMed

71.

Alperi A, Pascual I, Molina BD, Silva I, Lorca R, Hernández-Vaquero D, et al. Fever, malaise, and dyspnea in a diabetic heart transplant patient: a case report. Transplant Proc. 2017;49:1667–71. https://doi.org/10.1016/j.transproceed.2017.04.008.CrossRefPubMed

72.

Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741–51. https://doi.org/10.1056/NEJM199806113382407.CrossRefPubMed

Titel: Complications After Heart Transplantation in Adults: an Update
verfasst von: Kevin S. Shah
Jon A. Kobashigawa
Publikationsdatum: 01.06.2019
Verlag: Springer US
Erschienen in: Current Emergency and Hospital Medicine Reports / Ausgabe 2/2019
Elektronische ISSN: 2167-4884
DOI: https://doi.org/10.1007/s40138-019-00180-7

Neu im Fachgebiet AINS

Verschlechtert frühe Hyperoxie nach Reanimation die Prognose?

22.01.2025
Kardiopulmonale Reanimation
Nachrichten

Kommt es sehr früh nach einer kardiopulmonalen Reanimation zu einem Zustand der Hyperoxie, ist dies bei Patienten nach einem Herzstillstand mit schlechteren funktionellen Ergebnissen assoziiert. Das zeigt eine Sekundäranalyse der TTM-2-Studie.

Antibiotika bei Bakteriämie: 7 versus 14 Tage

21.01.2025
Sepsis
Nachrichten

Eine Bakteriämie lässt sich mit einer einwöchigen Antibiotikatherapie zumeist gut in den Griff bekommen: Die Sterberate ist nicht höher als unter zweiwöchiger Behandlung, zeigt eine Vergleichsstudie mit hospitalisierten Erkrankten. Allerdings muss die Therapie bei fast jedem Vierten verlängert werden.

Nasenstimulation lindert chronische Migräne

16.01.2025
Chronische Migräne
Nachrichten

Wird die Naseninnenseite durch Vibrationen stimuliert, kann dies offenbar die Zahl der Migränetage von Menschen mit chronischer Migräne deutlich senken. Darauf deuten die Resultate einer randomisiert-kontrollierten deutsch-finnischen Untersuchung.

Nackenschmerzen nach Bandscheibenvorfall: Muskeltraining hilft!

15.01.2025
Nackenschmerzen
Nachrichten

Bei hartnäckigen Schmerzen aufgrund einer zervikalen Radikulopathie schlägt ein Team der Universität Istanbul vor, lokale Steroidinjektionen mit einem speziellen Trainingsprogramm zur Stabilisierung der Nackenmuskulatur zu kombinieren.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Complications After Heart Transplantation in Adults: an Update